![Wafik S. El-Deiry: Great to run into my colleague David De Graff](https://oncodaily.com/pub/uploads/2024/06/IMG_2940.jpeg)
Wafik S. El-Deiry: Great to run into my colleague David De Graff
Wafik S. El-Deiry, shared a post on X:
“Great to run into my colleague, David De Graff, as we were both at Penn State News now he’s at Johnson & Johnson News.
We discussed our interest in bladder cancer at Legorreta Cancer Center at Brown University and The Warren Alpert Medical School of Brown University.
We have very high rates of bladder cancer in Rhode Island, some years we’re at 1 in the United States, or top 2-3. We don’t know why although we have good ideas.
It is a New England problem but Rhode Island is greatly affected across age groups, men and women. Rates are very very high among older men in Rhode Island.
Also telling him about opportunities for precision oncology trials in bladder cancer with the WIN Consortium.”
Source: Wafik S. El-Deiry/X
Wafik El-Deiry, MD, PhD, FACP, FRSM, is the Associate Dean for Oncologic Sciences at the Warren Alpert Medical School, and Director of the Legorreta Cancer Center at Brown University, and Director of the Joint Program in Cancer Biology at Brown University and affiliated hospitals.
Dr. El-Deiry discovered p21(WAF1) as a p53 target gene, cell cycle inhibitor, and tumor suppressor that explained the mammalian cell stress response. Dr. El-Deiry made important contributions to cell death signaling and our understanding of the sensitivity of tumors to chemotherapy. El-Deiry has more than 400 peer-reviewed publications and 5 edited books.